Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31

Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value

$0.18+0.00 (+0.95%)

Close on Nov 13, 2026Market cap $8.01MP/E –Yield –

Vistagen Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Vistagen Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Vistagen Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Jun 7, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VTGN.

Operating margin-2541.9% · median -586.2%

Net margin-2474.5% · median -691.8%

Advertisement
300 × 250

See a number that looks wrong?